



Annual General Meeting

Thursday, 20 January 2022 at 11.00am (AEDT)

Notice

This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 17 January 2021.

The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may require in evaluating a possible investment in OIL or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Neither OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to update any information subsequent to the issue of this presentation.

Future Performance

This presentation contains certain forward-looking statements and unaudited information including regarding the Company's future growth plans, strategies, products, operating performance, milestones, guidance, opinions, estimates, targets, goals, forecasts, earnings and financial position (Forward Looking Statements). The Forward Looking Statements, in this presentation are based on assumptions and contingencies which are subject to change without notice. Actual results and achievements could be significantly different from those expressed in or implied by this presentation. The Forward Looking Statements involve subjective judgements and assumptions as to future events which may or may not be correct and should not be relied upon as an indication or guarantee of future performance. No representation, warranty or assurance (express or implied) is given or made in relation to the achievement of any Forward Looking Statement by any person (including OIL).

Subject to any continuing obligations under applicable law, OIL disclaims any obligation or undertaking to provide any updates or revisions to any Forward Looking Statement in this presentation to reflect any change in expectations in relation to any such Forward Looking Statement or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will create an implication that there has been no change in the affairs of OIL since the date of this presentation.

Past performance

The operating and historical financial information in this presentation are not an indication of OIL's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. Past performance of OIL is not and cannot be relied upon as an indicator of (and provides no guidance as to) future performance.

Notice

Not an offer or financial product advice

This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure document required under the Corporations Act. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire securities and does not and will not form any part of any contract for acquisition of securities. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation (including, without limitation, the assumptions, uncertainties and contingencies which may affect the future operations of OIL and the impact that different future outcomes may have on OIL).

This presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in OIL's shares is subject to known and unknown risks, some of which are beyond the control of OIL. OIL does not guarantee any particular rate of return or the performance of OIL.

Liability

Neither OIL nor any of its officers, employees, officers, agents, consultants or advisers owe any duty (whether in equity, in tort or otherwise) to any investor in connection with this presentation nor do they have any liability (including, without limitation, in negligence) for any loss or damage arising from or in connection with this presentation, except to the extent that such liability may not lawfully be excluded.

To the maximum extent permitted by law, you acknowledge and agree that by taking part in this presentation you will not bring or institute any legal proceedings in contract, in tort, for breach of statutory duty or otherwise against OIL or any of its officers, employees, officers, agents, consultants or advisers in respect of any information provided to it in or in connection with this presentation.

Agenda

1. Welcome & Opening
2. Introductions
3. Apologies
4. Notice of Meeting
5. Format of Meeting
6. Chairman's Address
7. CEO/Managing Director's Presentation
8. General Questions
9. Voting Procedure
10. Items of Business
11. Proxies
12. Financial Statements & Reports
13. Resolutions

Chairman's Address



**Mr Robert Cooke,
Non-Executive Chairman**

Optiscan Board



Robert Cooke



Camile Farah



Phil Currie



Ron Song



Karen Borg

Chairman's Address

- 2021 was a year of significant progress for Optiscan from both a commercial and governance prospective
- Optiscan's technology has the potential to change standard of care for human cancer screening and surgery which is well recognised by medical community
- Significant Board invigoration over last 12 months
 - Mr Robert Cooke appointed Chair on 19 April 2021 and new non-executive directors appointed - Mr Ron Song [February 2021] and Ms Karen Borg [July 2021]
 - Professor Camile Farah appointed as a non-Executive Director in [May 2021], followed by his appointment as CEO/MD in December 2021 to replace outgoing MD Mr Darren Lurie
 - Mr Graham Mutton [July 2021] and Dr Phil Currie [following this AGM] resigned from the Board of Optiscan
- Board structures have been reviewed and key sub-committees are being established including a Risk and Audit committee, and a Remuneration committee
- The Company is well-funded – Capital Raising of A\$9.8m in September 2020

Chairman's Address

- In the last six months the Board undertook a company wide review which included a number of internal and external presentations – the findings from this review will form the basis to finalise our operational and strategic focus going forward under the new Board and Management
- Good progress was made in relation to the commercialization of Optiscan's key products
- Optiscan's established relationships with leading global medical technology companies, universities and hospitals are a strong endorsement of its unique technology
- The Board is committed to broadening and strengthening staff resources to enable accelerated regulatory, growth and sales strategies
- Optiscan is on the verge of the next stage in its exciting journey, as it seeks FDA approval for its InVivage® device for use in oral cancer, and trials are continuing in relation to other cancers and applications

Managing Director's Report



Prof Camile Farah, PhD MBA MAICD FAIM
CEO & Managing Director

Optiscan - Optimising for Growth

Key Themes

- Technology is proven and differentiated
- Clinical studies are providing opportunity to expand application footprint
- Innovation and clinical data will accelerate market entry into USA

Optiscan - Global leader in endomicroscopic imaging

Differentiated Technology



Hand-held confocal endomicroscopes for medical and research use



Application Opportunities

Clinical device (InVivage®) well progressed down FDA approval pathway

Clinical studies underway for cancer applications including oral, breast, cervical, esophageal

Co-operation with
ZEISS
CONVIVO neurosurgery









Market Expansion

Strong balance sheet and shareholder support









International distribution network for research device in Asia, N. America & Australia

Global market entry & distribution strategy for clinical launch

Unique ability to image different tissues




Proven ability to differentiate cancer vs normal




Excellent correlation with current gold standard histopathology




Endometrium







Mesothelioma



Pituitary adenoma



Oral carcinoma in situ



Strong Relationships and Partnerships

Established relationships with leading global medical technology companies, universities and hospitals



- Leaders in neurosurgery with digital pathology workflow recently approved by FDA



Oral/head and neck cancer studies

Memorial Sloan Kettering Cancer Center..



Breast cancer study at leading Melbourne hospitals



The Royal Melbourne Hospital



Epworth



BARROW
Neurological Institute

- One of most highly regarded neurological centres in US
- Neurosurgery clinical studies



Memorial Sloan Kettering Cancer Center..




QuantiDoc
Quantifying Robustness

Other applications

- Cervical & esophageal cancer
- ACL injury
- Tissue culture
- Eye health
- Fish health

Funding partners



MTPConnect
MedTech and Pharma Growth Centre



MEDICAL DEVICE
PARTNERING
PROGRAM



Selected 2021 publications demonstrating Optiscan technology

Brain



Redosing of Fluorescein Sodium Improves Image Interpretation During Intraoperative Ex Vivo Confocal Laser Endomicroscopy of Brain Tumors

Brain



Molecular Imaging of Glucose Metabolism for Intraoperative Fluorescence Guidance During Glioma Surgery

Cervical



PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures

Brain



Socio-Organizational Impact of Confocal Laser Endomicroscopy in Neurosurgery and Neuropathology: Results from a Process Analysis and Expert Survey

Brain




Intraoperative imaging of brain tumors with fluorescein: confocal laser endomicroscopy in neurosurgery. Clinical and user experience

Tendon



A multiscale study of morphological changes in tendons following repeated cyclic loading

Brain



Confocal Laser Microscopy in Neurosurgery: State of the Art of Actual Clinical Applications

Head & Neck



Fluorescein-Guided Panendoscopy for Head and Neck Cancer Using Handheld Probe-Based Confocal Laser Endomicroscopy: A Pilot Study

Gut



Rapid testing of gut permeability using oral fluorescein and confocal laser endomicroscopy in Zambian adults

Optiscan – Positioned for unique clinical impact

**Patients &
Advocates**

**Enhanced
accuracy of
decision
making and
outcomes**

**Clinicians &
hospital
executives**

**Reduced
negative
impacts and
cost savings**

**Markets &
healthcare
sector**

**Increased
demand,
maturity and
readiness**

***Optiscan
technology
provides high
resolution real-time
digital images***

***Ability for non-
invasive cellular
imaging & surgical
margin delineation***

***Digital platform
allows efficient
workflow
solutions and AI-
diagnostics***

Differentiated research and clinical devices for market diversification

FIVE2



Research Device

InVivage®



Clinical Device

FIVE2 Sales, Rentals and Loans

FIVE2 sales achieved



FIVE2 units on site



FIVE2 demos in progress



InVivage® Clinical Device

Overview

- Miniaturized hand-held rigid probe (4mm diameter tip)
- Real-time, sub-cellular live microscopic imaging
- High resolution images, 1000x real magnification
- Advanced software user interface
- DICOM-compatible/PACS-enabled
- Targeting cancer screening and surgical margin assessment

Clinical Applications



Oral Cancer



Breast Cancer



Cervical Cancer



InVivage® FDA submission process update

FDA approval process

- InVivage 510(k) submission through the FDA reduced timeframe pathway
- Aim to receive approval for use of images by clinicians, paving the way for follow-up FDA approval
- Submission to take place once all validation, verification and clinical activities are successfully completed
- Following submission, average time to clearance is approximately six months

Progress update

- Successfully passed multiple internal and external quality and safety tests
- Currently completing remaining tests, dedicating more resources for swift completion
- Dosing study completed and significant progress made in clinical study at Melbourne Dental School

Key Achievements in 2021 (1/2)

✓ Strengthening leadership and Board capabilities

- Appointment of Mr Robert Cooke, Ms Karen Borg and Mr Ron Song to Board
- Appointment of Prof Camile Farah as CEO & Managing Director



✓ Accelerating preparation for FDA application for InVivage approval in the US

- Progress in Melbourne Dental School imaging sets
- Advancement of internal and external and quality and safety testing for InVivage®



✓ Progression of US market entry planning

- Engagement with potential logistics and 3PL providers
- Development of marketing collateral for launch



Key Achievements in 2021 (2/2)

✓ Ongoing clinical studies to support oral/head & neck clinical applications

- Advancement of in vivo screening study at Australian Centre for Oral Oncology in Perth
- Commencement of 30 patient ex vivo study at University of Adelaide using FIVE2



✓ Completion of imaging for Breast Cancer Margin Assessment study

- Completed patient recruitment and imaging component of breast cancer margin assessment study (ex vivo) at Royal Melbourne Hospital, Frances Perry House and Epworth Hospital – 38 patients



✓ Sales of 2 FIVE2 systems to leading Australian Research Institutions

- Swinburne University as part of Victorian Government MedTechVic partnership
- The Walter and Eliza Hall Institute



FY21 Financial Highlights


✓ Strengthened balance sheet through a capital raising of \$9.8m

- Backing of Clermont Group as major shareholder



✓ FY21 Total Income (operating revenue and other income) of \$2.54m, up ~28% on FY20

- Increased distribution channels for FIVE2
- Continued orders from Carl Zeiss Meditec
- Grant income from InVivage® prototype and development



✓ FY21 EBITDA of (\$1.85m); FY21 Net operating cash outflow of (\$2.13m)

- Spending to underpin future growth including scalability in production, prototypes, and clinical studies



Oral Cancer study at Melbourne Dental School (1/2)

Results will assist with InVivage® FDA submission and open up clinical applications and markets

Summary

Aims

- Triage and monitor oral tissue health and escalate the diagnosis of oral cancer
- Validate use of fluorescent probe and mouth map software in performing digital biopsy

Key investigators

- Dr Tami Yap & Professor Michael McCullough

Collaborators

- Royal Melbourne Hospital, Memorial Sloan Kettering Cancer Center, Peter MacCallum Cancer Centre

No. of patients

- Up to 150 patients between Q4 2020 and Q4 2022


Current progress¹

- 40 patients imaged with topical fluorescein showing a variety of pathologies to be used in FDA submission
- Progress with other imaging dyes (49 with PARPi-FL, 46 with acriflavine)

1. As at December 20, 2021

Oral Cancer study at Melbourne Dental School (2/2)

Comparison of oral imaging using three dyes



Dr Tami Yap, University of Melbourne

- *Using Optiscan technology, clinically abnormal areas can be identified as either precancerous or cancerous compared to normal tissue*
- *Multiple potential dye applications demonstrating similar disease profiles*
- *Future potential for oral cancer screening and detection*

Oral Screening study at Australian Centre for Oral Oncology (1/2)

Results will assist with development of machine learning and artificial intelligence algorithms for diagnostic applications


Summary

Aims	<ul style="list-style-type: none">• Image a range of oral lesions (cancer, precancer, benign) compared to normal• Determine accuracy of correlation with standard histopathology• Build artificial intelligence platform for computer-assisted diagnosis
Key investigators	<ul style="list-style-type: none">• Professor Camile Farah, Oral Physician & Maxillofacial Pathologist
Collaborators	<ul style="list-style-type: none">• University of Texas MD Anderson Cancer Centre, Harvard University, Claritas HealthTech,
No. of patients	<ul style="list-style-type: none">• 123 patient datasets to Q4 2021
Current progress¹	<ul style="list-style-type: none">• Image analysis and histopathology correlation of topical acriflavine images• Image annotation and curation for machine learning analysis

1. As at December 13, 2021

Oral Screening study at Australian Centre for Oral Oncology (2/2)

Oral screening: Optiscan CLE technology vs. Histopathology



Prof Camille Farah, Australian Centre for Oral Oncology Research & Education

- *Using Optiscan technology, oral cancer can be differentiated from precancer and normal tissue*
- *Oral tissue/lesion microstructure correlates between confocal images and histopathology*
- *Future potential for AI applications and computer-assisted oral cancer detection*

Breast Cancer Margin Assessment study (1/2)

Results from the breast study will open up a new clinical application and market offering



Summary

Aim	<ul style="list-style-type: none">Determine if intraoperative imaging of excised breast tissue can detect positive surgical margins compared to standard pathology
Key investigators	<ul style="list-style-type: none">Professor Bruce Mann, Royal Melbourne and Royal Women's Hospital
Collaborators	<ul style="list-style-type: none">Dr Anand Murugasu, Dr Philip Currie, Lee McKerracher (Breast Cancer Network Australia), Frances Perry House, Epworth Freemasons
No. of Patients	<ul style="list-style-type: none">Imaged 38 patients and 44 discrete tumors and related cavity shaves
Current progress¹	<ul style="list-style-type: none">Image analysis and comparison to histopathology with encouraging findings

¹. As at January 17, 2022

Breast Cancer Margin Assessment study (2/2)

Invasive Carcinoma of the Breast: Optiscan CLE technology vs. Histopathology



- *Optiscan images mirror the current gold standard*
- *Optiscan technology can provide precise identification of cancer cells at surgery*
- *Future clinical studies are required to advance the path to commercialisation*

Optiscan - Immediate Priorities

1

- Accelerate FDA approval of InVivage®
- Progress focused US launch

2

- Enhance product functionality
- Drive product R&D

3

- Expand clinical applications
- Drive sales revenue through market growth

Optiscan - Future Perspectives

1

- **Expand development of InVivage® platform**

2

- **Advance miniaturization and dye alternatives**
- **Explore molecular imaging applications**

3

- **Target artificial intelligence applications¹**
- **Drive AI-related diagnostics²**

1. Source: McKinsey 2020

2. Source: BCG 2019

Optiscan – Towards global leadership in medical imaging & diagnostics



Thank You



Thank you for your attendance